Document Classification

Section Type: RESULTS

Text: By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84 % for CMF -- > tamoxifen versus 85 % for tamoxifen alone ; difference = -1 ; 95 % CI = -6 % to 4 % ; RR = 0. 99 ; 95 % CI = 0. 75 to 1. 30 ; P =. 92) or OS (5-year OS = 95 % for CMF -- > tamoxifen versus 93 % for tamoxifen alone ; difference = 2 % ; 95 % CI = -1 % to 5 % ; RR = 0. 95 ; 95 % CI = 0. 64 to 1. 40 ; P =. 80).